As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.
17 Analysts have issued a Autolus Therapeutics plc forecast:
17 Analysts have issued a Autolus Therapeutics plc forecast:
Jun '25 |
+/-
%
|
||
Revenue | 30 30 |
-
|
|
Gross Profit | -24 -24 |
-
|
|
EBITDA | -261 -261 |
-
|
EBIT (Operating Income) EBIT | -270 -270 |
-
|
Net Profit | -228 -228 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Head office | United Kingdom |
CEO | Christian Itin |
Employees | 649 |
Founded | 2014 |
Website | www.autolus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.